UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis

American journal of ophthalmology, 2010-07, Vol.150 (1), p.122-127.e5

2010

Volltextzugriff (PDF)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial

Optometry and vision science, 2018-03, Vol.95 (3), p.264-271

2018

Volltextzugriff (PDF)

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children

Clinical therapeutics, 2009-09, Vol.31 (9), p.1908-1921

2009

Volltextzugriff (PDF)

Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis

American journal of ophthalmology, 2021-09, Vol.229, p.288-300

2021

Volltextzugriff (PDF)

A Randomized, Multicenter Phase 3 Clinical Trial Evaluating Intracanalicular Dexamethasone Insert for the Treatment of Allergic Conjunctivitis

Clinical ophthalmology (Auckland, N.Z.), 2024-01, Vol.18, p.2671-2684

2024

Volltextzugriff (PDF)

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge

Annals of allergy, asthma, & immunology, 2010-07, Vol.105 (1), p.57-64

2010

Volltextzugriff (PDF)

Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

Ophthalmology and therapy, 2022-08, Vol.11 (4), p.1449-1461

2022

Volltextzugriff (PDF)

Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness

Current eye research, 2018-01, Vol.43 (1), p.43-51

2018

Volltextzugriff (PDF)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

Clinical ophthalmology (Auckland, N.Z.), 2019-01, Vol.13, p.403-413

2019

Volltextzugriff (PDF)

Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: A single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis

Clinical therapeutics, 2008-07, Vol.30 (7), p.1272-1282

2008

Volltextzugriff (PDF)

Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model

Journal of ocular pharmacology and therapeutics, 2017-03, Vol.33 (2), p.79-90

2017

Volltextzugriff (PDF)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model

Clinical ophthalmology (Auckland, N.Z.), 2018-01, Vol.12, p.2617-2628

2018

Volltextzugriff (PDF)

Antihistamines in Ocular Allergy: Are They All Created Equal?

Current allergy and asthma reports, 2011-06, Vol.11 (3), p.205-211

2011

Volltextzugriff (PDF)

Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube ® : a randomized clinical trial

Journal of asthma and allergy, 2019-03, Vol.12, p.71-81

2019

Volltextzugriff (PDF)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis

Journal of asthma and allergy, 2018-01, Vol.11, p.29-39

2018

Volltextzugriff (PDF)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5

Clinical ophthalmology (Auckland, N.Z.), 2014-01, Vol.8 (default), p.1495-1505

2014

Volltextzugriff (PDF)

Technical and clinical validation of an environmental exposure unit for ragweed

Journal of asthma and allergy, 2016-01, Vol.9, p.215-221

2016

Volltextzugriff (PDF)

Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing

Expert opinion on drug metabolism & toxicology, 2008-04, Vol.4 (4), p.453-461

2008

Volltextzugriff (PDF)

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis

Journal of ocular pharmacology and therapeutics, 2011-08, Vol.27 (4), p.385-393

2011

Volltextzugriff (PDF)

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

Allergy and asthma proceedings, 2012-05, Vol.33 (3), p.265-274

2012

Volltextzugriff (PDF)

A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis

Allergy and asthma proceedings, 2008-11, Vol.29 (6), p.644-653

2008

Volltextzugriff (PDF)

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study

Clinical therapeutics, 2004-08, Vol.26 (8), p.1237-1248

2004

Volltextzugriff (PDF)

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

Allergy and asthma proceedings, 2007-07, Vol.28 (4), p.427-433

2007

Volltextzugriff (PDF)

Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?

Allergy and asthma proceedings, 2009-03, Vol.30 (2), p.212-214

2009

Volltextzugriff (PDF)

Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis

Current medical research and opinion, 2005-05, Vol.21 (5), p.683-691

2005

Volltextzugriff (PDF)

1 – 25 von 377

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(322)
Mit Volltextzugriff
(313)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(263)
Life Sciences & Biomedicine
(200)
Humans
(173)
Female
(90)
Male
(89)
Middle Aged
(60)
Adult
(55)
Aged
(50)
Biological And Medical Sciences
(37)
Animals
(34)
Physical Sciences
(33)
Medical Sciences
(31)
Patients
(29)
General & Internal Medicine
(28)
Science & Technology - Other Topics
(28)
Technology
(28)
Adolescent
(27)
Medicine, General & Internal
(26)
Multidisciplinary Sciences
(25)
Child
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children

Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis

A Randomized, Multicenter Phase 3 Clinical Trial Evaluating Intracanalicular Dexamethasone Insert for the Treatment of Allergic Conjunctivitis

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge

Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: A single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis

Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model

Antihistamines in Ocular Allergy: Are They All Created Equal?

Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube ® : a randomized clinical trial

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5

Technical and clinical validation of an environmental exposure unit for ragweed

Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?

Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis

Suchergebnisse filtern